The Verge
Cover art for Google's AlphaGenome 2 maps disease at the cellular level

Google's AlphaGenome 2 maps disease at the cellular level

DeepMind's new AI model predicts how DNA mutations affect individual cell types, potentially revealing disease causes and treatment paths.

By ·

Nov 11, 2026

8 cards · 1m 50s · tap to begin

From · · · 1m 50s

Google's AlphaGenome 2 maps disease at the cellular level

DeepMind's new AI model predicts how DNA mutations affect individual cell types, potentially revealing disease causes and treatment paths.

In brief

DeepMind's new AI model predicts how DNA mutations affect individual cell types, potentially revealing disease causes and treatment paths. Google DeepMind released AlphaGenome 2, an AI model that predicts how genetic variants affect specific cell types, offering finer detail than previous models to help identify…

DeepMind's new genetics model

alphagenome-atlas-cover__background

Google DeepMind has unveiled AlphaGenome 2, an AI model designed to show how changes in DNA affect different cells.The model offers a much finer-grained view than its predecessor, potentially revealing disease-relevant effects in specific cells.

Why cell type matters

Nearly every cell in the human body carries the same DNA, but different cell types switch different genes on and off.

Training on millions of cells

AlphaGenome 2 was trained on more than one hundred million individual cell profiles across sixty eight tissues.

Predicting without retraining

Robert Hart

AlphaGenome 2 can make predictions about new types of cells and biological states without needing to be retrained.

Connecting genetics to disease

Adam Gayoso, a research scientist at Google DeepMind, says the breakthrough is tying human genetics to cell biology.

“tying human genetics to cell biology”

Why specificity matters for drugs

Žiga Avsec, Google DeepMind's genomics lead, told The Verge that specificity is vital for drug development. When you develop drugs, you are targeting specific proteins and specific cell types, making this kind of granularity essential.

“When you develop drugs, you're targeting specific proteins and specific cell types”

Computational trade-offs

AlphaGenome 2 is not replacing its predecessor yet. Its more detailed predictions come at a computational cost and are more expensive to produce than those of AlphaGenome, making it impractical for genome-wide atlases.

Available now for research

Google is making AlphaGenome 2 available for non-commercial research via the AlphaGenome API from today, with a limited private preview for commercial research.

What to remember

Google DeepMind released AlphaGenome 2, an AI model that predicts how genetic variants affect specific cell types, offering finer detail than previous models to help identify disease causes and guide drug development.

Read the original on The Verge

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on google deepmind and related topics.